Proposal for Tropifexor (LJN452, Novartis)

Overview of Therapeutic Candidate:
Tropifexor (LJN452) is a highly potent, non‐steroidal agonist of the Farnesoid X Receptor (FXR) that was developed by Novartis Pharmaceuticals through a rational drug design process aimed at overcoming the limitations of earlier bile acid–derived molecules such as obeticholic acid, which, although efficacious, were associated with undesirable side effects including pruritus and lipid profile alterations (Focaccia, 2024, pp. 49–52). It belongs to a novel class of synthetic FXR agonists that are non‐bile acid in nature, characterized by a unique “hammerhead” chemical scaffold which confers high receptor binding affinity with an EC₅₀ in the subnanomolar range (approximately 0.2 nM), a property that distinguishes it from earlier steroidal ligands (Chen et al., 2024, pp. 1–2). The design of tropifexor originated from iterative medicinal chemistry efforts to modify earlier scaffolds such as GW4064, a well‐known FXR agonist that demonstrated potent in vitro activity but suffered from issues related to poor bioavailability and potential hepatobiliary toxicity, thereby prompting a shift toward non‐steroidal, non–bile acid compounds with improved pharmacokinetic profiles (Ding et al., 2024, pp. 4–5). As part of the FXR agonist drug class, tropifexor capitalizes on the ability to regulate bile acid homeostasis, as well as lipid and glucose metabolism, which are critical pathophysiologic processes in liver metabolic diseases such as non‐alcoholic steatohepatitis (NASH) (Unknown Reference). Moreover, the synthesis and discovery of tropifexor are underpinned by structural insights into the ligand binding domain of FXR, enabling its high selectivity and potency that have been validated by both in vitro and in vivo studies (Hernandez et al., 2019, pp. 1–2).

Therapeutic History:
Tropifexor has an extensive preclinical history in rodent models of NASH, where it has been demonstrated to significantly reduce hepatic steatosis, inflammation, and fibrosis, thereby improving overall hepatic histology and biomarker profiles (Hernandez et al., 2019, pp. 2–4). Multiple studies have confirmed that tropifexor treatment in diet-induced NASH models, such as the AMLN model and the STAM model, leads to marked reductions in liver triglyceride levels, collagen deposition, and expression of pro-fibrogenic genes, which has been further corroborated by transcriptomic analyses showing enhancement of antioxidative gene expression patterns (Hernandez et al., 2019, pp. 7–9; Focaccia, 2024, pp. 106–109). Clinically, tropifexor is being evaluated in several Phase II clinical trials for NASH and related liver fibrotic conditions, with trial identifiers such as NCT03517540, NCT04065841, and NCT04147195 documenting its safety, tolerability, and preliminary efficacy as measured by reductions in liver enzymes and improvements in magnetic resonance imaging–proton density fat fraction (MRI-PDFF) (ClinicalTrials.gov, 2018). The therapeutic class of non‐steroidal FXR agonists, which includes compounds such as cilofexor and EDP-305, has been increasingly validated in clinical settings not only for NASH but also for cholestatic liver diseases, thereby building a historical precedent for the repurposing of tropifexor as a therapeutic candidate in metabolic liver conditions (Unknown Reference; Anfuso et al., 2020, pp. 10–11). In addition, early human studies have demonstrated that tropifexor exhibits a favorable pharmacokinetic profile with once-daily oral dosing, acceptable tolerability, and target engagement as evidenced by biomarker changes such as increased fibroblast growth factor 19 (FGF19) levels, which further supports its clinical development for NASH (Badman et al., 2020, pp. 1–2).

Mechanism of Action:
Tropifexor exerts its therapeutic effects primarily through activation of the nuclear receptor FXR, which is abundantly expressed in hepatocytes, cholangiocytes, and intestinal epithelial cells, and plays a pivotal role in regulating bile acid synthesis, lipid and glucose homeostasis, and inflammatory responses (Ding et al., 2024, pp. 2–4). Upon binding to FXR, tropifexor promotes a conformational change in the receptor that facilitates the recruitment of coactivator proteins and the formation of a heterodimer with the retinoid X receptor (RXR), which then binds to specific FXR response elements (FXREs) in the promoter regions of target genes (Hernandez et al., 2019, pp. 2–4). One critical downstream effect of FXR activation is the induction of the small heterodimer partner (SHP), a transcriptional corepressor that plays a key role in the suppression of sterol regulatory element-binding protein 1c (SREBP-1c), a master regulator of de novo lipogenesis in hepatocytes (Chen et al., 2024, pp. 12–15). The suppression of SREBP-1c results in a significant reduction in the synthesis of fatty acids and triglycerides within the liver, thereby alleviating hepatic steatosis (Cariello et al., 2021, pp. 7–8). Moreover, by lowering intracellular levels of malonyl-CoA—a substrate as well as an inhibitor of carnitine palmitoyltransferase 1 (CPT1)—tropifexor indirectly enhances mitochondrial beta-oxidation, promoting the breakdown and clearance of accumulated lipids (Geng et al., 2025, pp. 12–14). FXR activation by tropifexor also induces the expression of fibroblast growth factor 15/19 (FGF15/19) in the ileum, which, upon release into the circulation, acts on the liver to further suppress bile acid synthesis by downregulating cholesterol 7α-hydroxylase (CYP7A1), thus maintaining bile acid homeostasis and reducing hepatic stress (Ding et al., 2024, pp. 26–28). Additionally, transcriptomic analyses have revealed that tropifexor modulates gene networks associated with antioxidant responses and anti-inflammatory pathways, contributing to reduced oxidative stress and attenuation of fibrogenic signaling in the liver (Hernandez et al., 2019, pp. 7–9; Focaccia, 2024, pp. 123–125). These molecular interactions collectively support the hypothesis that tropifexor can rebalance hepatocyte lipid metabolism while mitigating inflammatory and fibrotic processes that contribute to NASH pathogenesis (Chen et al., 2024, pp. 8–10).

Expected Effect:
Based on its mechanistic profile, the expected effect of tropifexor in the context of NASH is a multi-pronged improvement in hepatic pathology; specifically, activation of FXR in hepatocytes is anticipated to result in a substantial suppression of de novo lipogenesis through the SHP-mediated inhibition of SREBP-1c, thereby reducing the synthesis and accumulation of fatty acids and triglycerides (Anfuso et al., 2020, pp. 9–10). This suppression is further complemented by a concomitant decrease in malonyl-CoA levels, which permits enhanced mitochondrial beta-oxidation of fatty acids and contributes to the clearance of excess lipids from the liver (Geng et al., 2025, p. 17). In preclinical studies, these molecular events have translated into marked reductions in liver fat content, as measured by both biochemical assays and imaging modalities such as MRI-PDFF, along with improvements in liver enzyme profiles (Badman et al., 2020, pp. 11–14; ClinicalTrials.gov, 2020). Additionally, the anti-inflammatory effects mediated by tropifexor are expected to manifest as lower serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as reductions in circulating pro-inflammatory cytokines, all of which are well-documented indicators of hepatic injury and inflammation in NASH patients (ClinicalTrials.gov, 2018; Unknown Reference). Furthermore, the downstream induction of genes involved in antioxidative stress responses and the suppression of profibrotic mediators suggest that tropifexor may also ameliorate liver fibrosis, a key concern in the progression of NASH to cirrhosis (Hernandez et al., 2019, pp. 7–9; Focaccia, 2024, pp. 106–109). Taken together, these effects are expected to not only reverse the morphological and functional derangements associated with NASH but also to improve overall liver metabolic homeostasis, which may ultimately translate into better clinical outcomes for patients (Badman et al., 2020, pp. 14–16).

Overall Evaluation:
In evaluating tropifexor as a therapeutic candidate for NASH, several strengths are evident: its subnanomolar potency and high selectivity for FXR make it a highly attractive agent from a pharmacodynamic perspective, as these features ensure robust engagement of the target receptor with minimal off-target effects (Chen et al., 2024, pp. 1–2; Focaccia, 2024, pp. 49–52). The extensive preclinical data demonstrating its efficacy in reducing hepatic steatosis, inflammation, and fibrosis in multiple rodent models lends further support to its potential utility in human NASH, and early-phase clinical trials have provided encouraging signals in terms of biomarker improvements and tolerability profiles (Hernandez et al., 2019, pp. 2–4; Unknown Reference). Moreover, its mechanism of action—encompassing the dual ability to suppress de novo lipogenesis via inhibition of SREBP-1c and to promote mitochondrial beta-oxidation by decreasing malonyl-CoA levels—aligns well with the current pathophysiologic understanding of NASH, where impaired lipid metabolism plays a central role (Geng et al., 2025, pp. 12–14; Ding et al., 2024, pp. 26–28). Additionally, tropifexor’s ability to modulate inflammatory and fibrogenic pathways through FXR activation may offer a significant clinical advantage in halting or even reversing the progression of liver fibrosis, a notoriously difficult-to-treat component of advanced NASH (Focaccia, 2024, pp. 106–109; Anfuso et al., 2020, pp. 10–11).

Nonetheless, there are important weaknesses and potential risks that warrant cautious consideration. One of the main challenges associated with FXR agonists, including tropifexor, is the dose-dependent occurrence of pruritus, which has been observed clinically and can limit patient compliance if not properly managed (Badman et al., 2020, pp. 8–10; Unknown Reference). Moreover, while the preclinical models have shown impressive short-term efficacy, some long-term studies and preclinical observations raised concerns regarding hepatomegaly, increased hepatocyte proliferation, and potential pro-carcinogenic signals when FXR pathways are over-activated, although these signals remain to be definitively substantiated in human trials (Focaccia, 2024, pp. 123–125; Bak & Hsu, 2020, pp. 14–17). There are also potential metabolic side effects to consider; even though tropifexor appears to have an improved lipid profile compared to bile acid–derived agonists, ongoing vigilant monitoring of plasma cholesterol levels and other lipid parameters will be essential in clinical settings (Anfuso et al., 2020, pp. 9–10; Ding et al., 2024, pp. 17–18). Another area of potential limitation is the risk of off-target effects associated with global FXR activation in tissues beyond the liver and intestine, which could lead to unforeseen complications in long-term therapy if not carefully managed through dosage optimization and patient selection (Badman et al., 2020, pp. 11–14).

Overall, tropifexor represents a promising and mechanistically well-supported therapeutic candidate for NASH, offering robust FXR activation that can rebalance hepatocyte lipid metabolism while also mitigating inflammatory and fibrotic processes key to the disease’s progression (Hernandez et al., 2019, pp. 7–9; Ding et al., 2024, pp. 26–28). Its high potency, good pharmacokinetic properties, and favorable early clinical signals underscore its potential as part of the next generation of NASH therapies. However, further large-scale and long-term clinical studies will be necessary to fully evaluate its safety profile, particularly with respect to pruritus, lipid alterations, and any potential pro-tumorigenic risks associated with chronic FXR activation (ClinicalTrials.gov, 2020; Unknown Reference; Focaccia, 2024, pp. 106–109). In summary, while tropifexor shows significant promise for the treatment of NASH, its future utility will depend on careful dose optimization, patient stratification, and comprehensive post-marketing surveillance to ensure that its potent biological effects translate into a meaningful clinical benefit with an acceptable risk profile (Badman et al., 2020, pp. 14–16; Geng et al., 2025, p. 17).

In conclusion, tropifexor’s robust preclinical efficacy, validated mechanism of action via FXR activation, and supportive early clinical data collectively suggest that it could serve as an effective therapy for NASH if its potential side effects are properly managed. Given the complex pathology of NASH—which encompasses steatosis, inflammation, and fibrosis—tropifexor’s multifaceted mechanism, leading to decreased lipogenesis, enhanced fatty acid oxidation, modulation of bile acid synthesis, and anti-inflammatory as well as antifibrotic effects, positions it as a strong candidate for further development (Hernandez et al., 2019, pp. 2–4; Ding et al., 2024, pp. 2–4). The current data emphasize both the promise and challenges of advancing tropifexor into late-stage clinical trials and, ultimately, into clinical practice, where its ability to restore metabolic equilibrium and improve liver histology might offer substantial benefits for patients suffering from non-alcoholic steatohepatitis (Anfuso et al., 2020, pp. 10–11; Unknown Reference). Therefore, recruiting further evidence through well-designed Phase III trials as well as mechanistic studies aimed at unraveling long-term effects will be critical to establishing tropifexor as a cornerstone in the therapeutic armamentarium against NASH (ClinicalTrials.gov, 2019; Focaccia, 2024, pp. 49–52).

References
Anfuso, B., Tiribelli, C., Adorini, L., & Rosso, N. (2020). Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Scientific Reports. https://doi.org/10.1038/s41598-020-58562-x

Badman, M. K., Chen, J., Desai, S., Vaidya, S., Neelakantham, S., Zhang, J., Gan, L., Danis, K., Laffitte, B., & Klickstein, L. B. (2020). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non–bile acid FXR agonist tropifexor (LJN452) in healthy volunteers. Clinical Pharmacology in Drug Development, 9, 395–410. https://doi.org/10.1002/cpdd.762

Bak, P. M. N., & Hsu, C. (2020). Analysis of the non-alcoholic steatohepatitis (NASH) drug pipeline & market. [Unknown Journal].

Cariello, M., Piccinin, E., & Moschetta, A. (2021). Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH. Cellular and Molecular Gastroenterology and Hepatology, 11, 1519–1539. https://doi.org/10.1016/j.jcmgh.2021.01.012

Chen, J., Wang, R., Xiong, F., Sun, H., Kemper, B., Li, W., & Kemper, J. (2024). Hammerhead-type FXR agonists induce an enhancer RNA FICOR that ameliorates nonalcoholic steatohepatitis in mice. eLife. https://doi.org/10.7554/eLife.91438.3

ClinicalTrials.gov. (2018). Study of safety, tolerability, and efficacy of a combination treatment of LJN452 and CVC in adult patients with NASH and liver fibrosis (NCT03517540). Retrieved from https://clinicaltrials.gov/ct2/show/NCT03517540

ClinicalTrials.gov. (2019). Efficacy, safety and tolerability of the combination of tropifexor & licogliflozin and each monotherapy, compared with placebo in adult patients with NASH and liver fibrosis (NCT04065841). Retrieved from https://clinicaltrials.gov/ct2/show/NCT04065841

ClinicalTrials.gov. (2020). Study of various treatments in non-alcoholic fatty liver disease (NAFLD) patients who have aspects of non-alcoholic steatohepatitis (NCT04147195). Retrieved from https://clinicaltrials.gov/ct2/show/NCT04147195

Ding, C., Wang, Z., Dou, X., Yang, Q., Ning, Y., Kao, S., Sang, X., Hao, M., Wang, K., Peng, M., Zhang, S., Han, X., & Cao, G. (2024). Farnesoid X receptor: From structure to function and its pharmacology in liver fibrosis. Aging and Disease. https://doi.org/10.14336/ad.2023.0830

Focaccia, E. (2024). Exploring the effects of different FXR agonists on progression of non-alcoholic steatohepatitis and its transition to hepatocellular carcinoma. [Unknown Journal].

Geng, W., Liao, W., Cao, X., & Yang, Y. (2025). Therapeutic targets and approaches to manage inflammation of NAFLD. Biomedicines, 13, Article 393. https://doi.org/10.3390/biomedicines13020393

Hernandez, E. D., Zheng, L., Kim, Y., Fang, B., Liu, B., Valdez, R. A., Dietrich, W. F., Rucker, P. V., Chianelli, D., Schmeits, J., Bao, D., Zoll, J., Dubois, C., Federe, G. C., Chen, L., Joseph, S. B., Klickstein, L. B., Walker, J., Molteni, V., McNamara, P., Meeusen, S., Tully, D. C., Badman, M. K., Xu, J., & Laffitte, B. (2019). Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents. Hepatology Communications, 3, 1085–1097. https://doi.org/10.1002/hep4.1368
